Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue

Source The Motley Fool

Key Points

  • Johnson & Johnson currently exhibits a stronger overall revenue profile than Pfizer by maintaining consistently higher absolute sales volume across every reported period.

  • Over roughly the last eight quarters, Johnson & Johnson achieved steady quarter-over-quarter revenue growth, while Pfizer experienced a volatile quarter-over-quarter trajectory marked by repeating fluctuations.

  • Investors should closely monitor whether the revenue gap between the two companies continues to widen in upcoming quarters or eventually begins to narrow.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

Johnson & Johnson: Steady Upward Recent Revenue Growth

Johnson & Johnson (NYSE:JNJ) primarily generates revenue by developing and selling pharmaceutical and medical technology products globally.

It recently entered a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront, and it received U.S. Food and Drug Administration approval for a new targeted cancer therapy.

Pfizer: Uneven and Volatile Recent Revenue Patterns

Pfizer (NYSE:PFE) primarily generates revenue by developing, manufacturing, and commercializing prescription medicines and vaccines for individuals worldwide.

It recently announced a $1.5 billion funding agreement with Blackstone Life Sciences, and it secured expanded regulatory approval from the U.S. Food and Drug Administration for a cancer treatment regimen.

Why Revenue Matters for Investors

Revenue here refers to the data provider's standardized income-statement revenue line item, and it shows the total money a business brings in from sales before deducting any operating costs.

Johnson & Johnson vs. Pfizer Revenue chart

Johnson & Johnson vs. Pfizer Revenue over the last 8 quarters.

Quarterly Revenue for Johnson & Johnson and Pfizer

Calendar quarterJohnson & Johnson RevenuePfizer Revenue
Q4 2024$22.5 billion (quarter ended Dec. 29, 2024)$17.8 billion (quarter ended Dec. 31, 2024)
Q1 2025$21.9 billion (quarter ended March 30, 2025)$13.7 billion (quarter ended March 30, 2025)
Q2 2025$23.7 billion (quarter ended June 29, 2025)$14.7 billion (quarter ended June 29, 2025)
Q3 2025$24.0 billion (quarter ended Sept. 28, 2025)$16.7 billion (quarter ended Sept. 28, 2025)
Q4 2025$24.6 billion (quarter ended Dec. 28, 2025)$17.6 billion (quarter ended Dec. 31, 2025)
Q1 2026$24.1 billion (quarter ended March 29, 2026)$14.4 billion (quarter ended March 29, 2026)
Q2 2026$25.3 billion (quarter ended June 28, 2026)$15.0 billion (quarter ended June 28, 2026)
Q3 2026$25.4 billion (quarter ended Sept. 27, 2026)$16.6 billion (quarter ended Sept. 27, 2026)

Foolish Take

First off, don't be concerned about the drops in revenue you see in the chart for both companies as you read left to right. That reflects the seasonality of the businesses, which often can be traced back to doctors and patients loading up on prescriptions toward the end of a calendar year, when many patients have met their health insurance deductibles.

While ideally, a quarterly revenue chart would show rising bars from left to right, this seasonality means a better evaluation would be to compare each quarter to its prior-year quarter. For instance, JNJ's third quarter of 2026 saw positive gains over the third quarter of 2025. Yet Pfizer's sales actually show a slight dip in Q3 2026 compared to the same period in 2025. That's a red flag for investors to pay attention to.

We also do see less fluctuation from JNJ, in part because the business has 28 products and platforms that each generate more than $1 billion in annual sales. Pfizer, meanwhile, is trying to recover from a post-COVID-19 letdown, with fewer people getting the COVID vaccine each year as we get further from the pandemic.

Data source: Financial Modeling Prep. Data as of Nov. 17, 2026.

Should you buy stock in Johnson & Johnson right now?

Before you buy stock in Johnson & Johnson, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*

Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 17, 2026.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Nvidia Q3 Earnings Loom as Market Expects Revenue Near $109 Billion: Can NVDA Stock Hold $150? As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
Author  TradingKey
10 hours ago
As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
placeholder
Gold Price Forecast: Gold Holds Key $3,850 Support, US October Retail Sales May Drive Rebound Toward $4,000As of the Asian session on Tuesday (November 17), gold (XAUUSD) maintained a weak rebound intraday today after recent continuous declines to a nearly one-year low, edging up 0.2% during t
Author  TradingKey
10 hours ago
As of the Asian session on Tuesday (November 17), gold (XAUUSD) maintained a weak rebound intraday today after recent continuous declines to a nearly one-year low, edging up 0.2% during t
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 17, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
Author  Mitrade
13 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
placeholder
Australian Dollar declines below 0.6750 after RBA minutes, US Retail Sales data in focusThe AUD/USD pair trades with mild losses around 0.6730 during the early Asian session on Tuesday.
Author  FXStreet
17 hours ago
The AUD/USD pair trades with mild losses around 0.6730 during the early Asian session on Tuesday.
placeholder
Bitcoin Plunges 13% in a Week as Market Retreats to $60,000 LevelBitcoin plunged 13% over the past seven days as bullish defense lines crumbled in succession, officially kicking off the battle to defend the $60,000 mark.On November 16, following a viol
Author  TradingKey
Yesterday 10: 05
Bitcoin plunged 13% over the past seven days as bullish defense lines crumbled in succession, officially kicking off the battle to defend the $60,000 mark.On November 16, following a viol
goTop
quote